HiFiBio partners with CoVIC for SARS-CoV-2 antibody therapies

By The Science Advisory Board staff writers

August 17, 2020 -- HiFiBio Therapeutics and the Coronavirus Immunotherapy Consortium (CoVIC) will collaborate to develop SARS-CoV-2-neutralizing antibodies with potential therapeutic and prophylactic applications.

HiFiBio has submitted 10 distinct mono- and bispecific antibodies to CoVIC for in vitro and in vivo testing. The company will get a first look into the performance of its antibodies compared to other submitted antibodies and will explore synergies among them for potential combinational therapies. Together, the collaboration seeks to accelerate development pipelines to protect vulnerable individuals from COVID-19 and bring successful immunotherapies to COVID-19 patients.

The antibodies were developed by leveraging HiFiBio's proteomics and proprietary single-cell profiling technologies. The company's Drug Intelligent Science technology allows antibody therapies to be matched with biomarkers to predict patient response.

The company is also preparing an investigational new drug application with the U.S. Food and Drug Administration for HFB30132A, a SARS-CoV-2-neutralizing antibody for the treatment of COVID-19 patients. The antibody has been evaluated in preclinical studies and a phase I clinical study is planned for later this summer.

Copyright © 2020 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here